Peer Ambassador in Gyn Onc Trials
NCT07915336, Not applicable, Enrolling by invitation, Abramson Cancer Center at Penn Medicine
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Peer Ambassador in Gyn Onc Trials | ClinicalTrials.gov |
| NCT number | NCT07915336 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 125 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Abramson Cancer Center at Penn Medicine | ClinicalTrials.gov |
| Conditions | Ovarian Cancer | ClinicalTrials.gov |
| Interventions | Mentee encounters | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Attitude about enrolling in trials | 12 months from enrollment | Participants' attitudes about enrolling in trials will be assessed through the Attitudes Toward Cancer Trials Scales (ACTS). Scores will range from 18-126. The difference between pre and post intervention scores will be assessed. Higher scores indicate a better attitude. | ClinicalTrials.gov |
| Primary | Intent to Enroll in Trials | 12 months from enrollment | Participants' intent to enroll in trials will be assessed through a previously validated Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) instrument. Responses will range from yes or no. | ClinicalTrials.gov |
| Secondary | Mentee knowledge regarding clinical trials before and after discussion sessions | Within 12 weeks of completing all sessions | This will be assessed using a knowledge of clinical trials questionnaire. Scores will range from 0-12. The difference between pre and post intervention scores will be assessed. Higher scores indicate greater knowledge of clinical trials. | ClinicalTrials.gov |
| Secondary | Feasibility of this ambassador program | 12 months from study start | Feasibility of this ambassador program will be assessed using the Feasibility of Intervention Measure (FIM). Scores will range from 1-5. Higher scores indicate greater feasibility of the program. | ClinicalTrials.gov |
| Secondary | Acceptability of this ambassador program | 12 months from study start | Acceptability will be assessed using the Acceptability of Intervention Measure (AIM). Scores will range from 1-5. Higher scores indicate greater acceptability of the program. | ClinicalTrials.gov |
| Secondary | Proportion of mentees in this program who enrolled onto a clinical trial | 12 months from study start | Mentees will be followed for 12 months and it will be documented if they enroll in a clinical trial. The percent of mentees who enroll in a clinical trial will be calculated. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)